Arimoclomol Has Potential to Slow ALS Patients’ Functional Decline, Phase 2/3 Trial Shows

A Phase 2/3 clinical trial showed that arimoclomol has the potential to slow ALS patients’ functional decline, according its maker, CytRx Corporation. Arimocolomal did better than a placebo at slowing the decline in patients with a rapidly worsening disease, although the differences were not statistically significant, researchers said. It was also…

As a newly diagnosed ALS patient attending an ALS clinic, I received a packet filled with various brochures and helpful information. Attached to one pamphlet I found a small card with the words, “Taking care of myself is not an act of indulgence, it is an act…

Amyotrophic lateral sclerosis, also know as ALS or Lou Gehrig’s disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. There are two different types of ALS: sporadic and familial. To help you understand more about this disease, we’ve put together a list with…

Some immune cells in the brain can protect it from the damaging effects of faulty TDP-43 protein, preventing the progression of amyotrophic lateral sclerosis in mice, University of Pennsylvania researchers report. The findings challenged a long-held assumption that the immune cells play a role in damaging nerve cells, the team…

In recognition of Rare Disease Day 2018, Bionews Services — which publishes this website — will attend and report on three relevant conferences in the U.S. dealing with policies and programs of importance to patients and their families. The three are among 50 events in 32 states…

Researchers at the NYU School of Medicine described a new strategy to preserve muscle function in a mouse model of amyotrophic lateral sclerosis (ALS). The finding could have implications for the treatment of alterations that occur in the early phases of ALS, also known as Lou Gehrig’s disease. The…

This WKBW TV video is about Marcia from North Tonawanda. Marcia was diagnosed with amyotrophic lateral sclerosis (ALS) two years ago. MORE: Seven hundred sites enrolled in new infusion center directory for ALS patients prescribed Radicava Marcia’s family held a “Music for Marcia” fundraising event featuring local musicians…

ALS patients who took Rilutek (riluzole) for at least three-fourths of the time they had their disease survived longer than those who took it less, an Italian study reports. Rilutek is the first ALS treatment to obtain U.S. Food and Drug Administration approval. Scientists are still not sure how it…

Speech-language pathologists (SLPs) or speech-language therapists (SLTs) do much more than help people with speech problems such as stuttering or mispronouncing words. For children and adults with neuromuscular disorders like spinal muscular atrophy (SMA), muscular dystrophy (MD) and amyotrophic lateral…

Researchers homed in on how a particular protein, called semaphorin 3A (Sema3A), affects the survival of motor neurons in both the brain and spinal cord in models of amyotrophic lateral sclerosis (ALS). Their study, “ALS-related human cortical and motor neurons survival is differentially affected by Sema3A,” appeared in the…